BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27196775)

  • 1. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.
    Hu S; Ueda M; Stetson L; Ignatz-Hoover J; Moreton S; Chakrabarti A; Xia Z; Karan G; de Lima M; Agrawal MK; Wald DN
    Mol Cancer Ther; 2016 Jul; 15(7):1485-1494. PubMed ID: 27196775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSK3 is a regulator of RAR-mediated differentiation.
    Gupta K; Gulen F; Sun L; Aguilera R; Chakrabarti A; Kiselar J; Agarwal MK; Wald DN
    Leukemia; 2012 Jun; 26(6):1277-85. PubMed ID: 22222598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.
    Gupta K; Stefan T; Ignatz-Hoover J; Moreton S; Parizher G; Saunthararajah Y; Wald DN
    Cancer Res; 2016 May; 76(9):2743-53. PubMed ID: 26964622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
    Zhang XW; Shen X; Long WY; Xiao H; Li FJ; Xing S; Xiong GL; Yu ZY; Cong YW
    Int J Hematol; 2021 Feb; 113(2):254-262. PubMed ID: 33074481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 6. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia.
    Zhou C; Du J; Zhao L; Liu W; Zhao T; Liang H; Fang P; Zhang K; Zeng H
    Cell Death Dis; 2021 Mar; 12(3):231. PubMed ID: 33658491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
    Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
    J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
    Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
    Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
    Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
    Wu D; Wang W; Chen W; Lian F; Lang L; Huang Y; Xu Y; Zhang N; Chen Y; Liu M; Nussinov R; Cheng F; Lu W; Huang J
    Haematologica; 2018 Sep; 103(9):1472-1483. PubMed ID: 29880605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
    Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
    Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
    Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
    Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
    Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
    Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
    Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
    PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents.
    Shen X; Xiong GL; Jing Y; Xiao H; Cui Y; Zhang YF; Shan YJ; Xing S; Yang M; Liu XL; Dong B; Wang LS; Luo QL; Yu ZY; Cong YW
    Cancer Lett; 2015 Jan; 356(2 Pt B):686-96. PubMed ID: 25449427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of an LC-MS/MS method for quantitative determination of GS87, a novel antineoplastic agent, in mouse plasma.
    Kunati SR; Yang S; Wald D; Xu Y
    J Pharm Biomed Anal; 2018 May; 153():145-151. PubMed ID: 29482106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia.
    Callens C; Coulon S; Naudin J; Radford-Weiss I; Boissel N; Raffoux E; Wang PH; Agarwal S; Tamouza H; Paubelle E; Asnafi V; Ribeil JA; Dessen P; Canioni D; Chandesris O; Rubio MT; Beaumont C; Benhamou M; Dombret H; Macintyre E; Monteiro RC; Moura IC; Hermine O
    J Exp Med; 2010 Apr; 207(4):731-50. PubMed ID: 20368581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells.
    Zhou X; Fang Y; Jing H; Zhong L; Luo P; Song H; Yang B; He Q
    Mol Carcinog; 2013 Jan; 52(1):18-28. PubMed ID: 22006557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.